Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study
Our findings provide genetic evidence supporting the efficacy and safety of LPL pathway activation therapies for the prevention of coronary artery disease and type 2 diabetes, alone or in combination with statins or PCSK9 inhibitors.
Authors
- Marie‐Joe Dib (ORCID: https://orcid.org/0000-0001-7591-5684)
- Éloi Gagnon (ORCID: https://orcid.org/0000-0002-7483-1371)
- Stephen O. Brennan (ORCID: https://orcid.org/0000-0002-3224-1621)
- Dominique Chabot
- Héléne T. Cronjé (ORCID: https://orcid.org/0000-0001-6855-8324)
- Dipender Gill (ORCID: https://orcid.org/0000-0001-7312-7078)
- Sébastien Thériault (ORCID: https://orcid.org/0000-0003-1893-8307)
- Benoît J. Arsenault (ORCID: https://orcid.org/0000-0003-2240-8456)
- Shuai Yuan (ORCID: https://orcid.org/0000-0001-5055-5627)
- Stephen Burgess (ORCID: https://orcid.org/0000-0001-5365-8760)
Institutions
- University of Copenhagen (DK)
- Mater Misericordiae University Hospital (IE)
- Karolinska Institutet (SE)
- Sequoia Sciences (United States) (US)
- MRC Biostatistics Unit (GB)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Department of Public Health (US)
- Université Laval (CA)
- University of Pennsylvania (US)
Publication Details
- Journal
- Circulation Genomic and Precision Medicine
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1161/circgen.124.004933
- Citations
- 3
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.16